Siemens Medical Solutions Usa, Inc.

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers, is a foreign-owned subsidiary of Siemens Aktiengesellschaft that manufactures and services medical imaging equipment—MRI systems, CT scanners, X-ray systems, nuclear medicine, and PET equipment—to federal healthcare agencies as a prime contractor. The company competes exclusively on a full-and-open basis with no SBA set-aside designations, drawing $9.93 billion in combined potential value across 9,609 awards since 1985 and maintaining a federal services footprint spanning 81 customer agencies.

Siemens Medical Solutions' federal portfolio centers on medical capital equipment procurement, installation, maintenance, repair, and software support. Recent representative work includes a $12.1 million firm fixed-price purchase order from the National Institute of Mental Health (September 2026) for a MAGNETOM Terra.X Impulse Edition 7-Tesla MRI system with 18-to-24 month project management, turnkey installation, clinical training, and room preparation labor; a $3.5 million delivery order under the DLA Medical Capital Equipment Program (September 2026) from the National Acquisition Center for a PET-CT modality at St. Louis VA Medical Center; and a $2.97 million purchase order from NIMH (September 2026) for hardware and software upgrades to TERRA MRI systems. The company's work spans clinical settings, diagnostic equipment upgrades, emergency repairs, and preventive maintenance contracts with service periods extending five years.

Customer concentration is extreme and dominated by the Department of Veterans Affairs and Defense Logistics Agency. The top five funding agencies account for 85% of combined potential value, led by the Defense Logistics Agency Troop Support Medical (1,312 awards, $5.66 billion), the VA National Acquisition Center (1,402 awards, $1.24 billion), and the VA Veterans Integrated Service Network 12 (947 awards, $1.17 billion). The VA system represents the preponderant majority of Siemens's federal footprint—the company holds a position on multiple Veterans Integrated Service Networks and operates as the de facto sole-source provider for Siemens-branded diagnostic imaging equipment across the VA healthcare system.

Siemens operates on the DLA Medical Capital Equipment Program, a master IDIQ vehicle under which it holds 3,164 task orders valued at $2.55 billion in combined potential value. The company also holds several significant single-award indefinite-delivery contracts: an Indefinite Delivery Contract V797P6029B (1,411 task orders, $717.5 million), an Indefinite Delivery Contract SPM20002D8314 (292 task orders, $301.4 million), and comparable vehicles. Task orders flow continuously through these parent vehicles, with 207 new awards recorded in 2026 year-to-date.

Within the next twenty-four months, 299 awards with ultimate completion dates face recompete exposure, representing $406.7 million in combined potential value and creating significant pipeline opportunity for competitors and recompete risk for Siemens. Activity has been relatively flat—318 awards in 2022, 340 in 2023, 308 in 2024, declining to 281 in 2025 and 207 in 2026 through mid-October—suggesting stable but not growth-trajectory engagement.

On Service Contract Inventory (SCI) reporting, Siemens invoiced $198.2 million across federal service contracts above the $150,000 threshold from FY2022 through FY2025, with invoicing rising from $41.7 million in FY2022 to $58.8 million in FY2025. SCI-reported FTE counts show a precipitous decline from 12.1 FTEs in FY2022 to 6.3 FTEs in FY2025, indicating that while invoicing has grown modestly, the company has scaled delivery through higher-value-per-hour labor. Government-paid hourly rates on SCI contracts cluster at a median of $3,082.59/hr, with the 90th percentile at $7,906.94/hr and the 10th percentile at $836.63/hr—a wide spread reflecting the diversity of engineering, technical, and field service labor across medical equipment maintenance and installation work.

Siemens Medical Solutions operates as a fully integrated prime contractor and does not rely on subcontractors for federal service delivery. Across SCI-reportable prime contracts, subcontractor hours average 0% of total contractor hours. The company reports only a single named subcontractor across its entire SCI footprint, underscoring its preference for direct internal execution of equipment manufacturing, installation, maintenance, and training services. This integration model aligns with its role as original equipment manufacturer—proprietary technical expertise, supply chain control, and warranty compliance favor in-house delivery rather than subcontracting.

The company holds federal grant sub-award activity as well. Recent sub-awards include participation in a Bioengineering Research Partnership with Massachusetts General Hospital (August 2026) supporting clinical translation of a 7-Tesla MRI RF coil, a precision screening cost-effectiveness study at UT Southwestern Medical Center (February 2026), and a flat panel detector project for breast cancer detection at SUNY Research Foundation (September 2025). These grants represent smaller ancillary engagement relative to its dominant contract footprint but signal research-oriented technology development complementary to its core medical imaging equipment business.

As a foreign-owned, for-profit subsidiary of the Siemens conglomerate, Siemens Medical Solutions USA competes on full-and-open terms across federal healthcare procurement. Its position as original equipment manufacturer of Siemens-branded diagnostic imaging systems and its established sole-source justifications on equipment-specific repairs and upgrades create strong incumbent advantage across the VA and DLA medical capital equipment landscape. The company's federal revenue concentration in medical imaging equipment procurement and maintenance services, lack of subcontracting engagement, and deep entrenchment in the DLA Medical Capital Equipment Program IDIQ vehicle architecture position it as a critical infrastructure vendor within the federal healthcare enterprise—but one facing recompete exposure and customer acquisition challenges outside the VA/DLA ecosystem.